| You are here: Home: BCU 2|2002: Editor's Note: Select abstracts
SELECT ABSTRACTS
2001 San Antonio Breast Cancer Symposium
Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women. Breast Cancer Res Treat 2001;69(3): Abstract 8.
Mass R et al. Improved survival benefit from Herceptin (trastuzumab) and chemotherapy in patients selected by fluorescence in situ hybridization. Breast Cancer Res Treat 2001; Abstract 18.
Miles D et al. Survival benefit with Xeloda (capecitabine)/docetaxel vs docetaxel: Analysis of post-study therapy. Breast Cancer Res Treat 2001; Abstract 442.
Twelves C et al. Adding Xeloda (capecitabine) to docetaxel significantly improves survival and does not compromise quality of life in patients with metastatic breast cancer. Breast Cancer Res Treat 2001; Abstract 542.
Vukelja SJ et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: Latest results. Breast Cancer Res Treat 2001; Abstract 352.
Back
|
